Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in...
-
FDA granted de novo class II for cobas EBV test following the agency’s Breakthrough Device designationAccurate monitoring of Epstein-Barr virus DNA levels is critical, as they are associated with a...
-
Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain This approval shows the value of combining genomic profiling with precision medicine...
-
Basel, 31 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab) plus Cotellic® (cobimetinib) and Zelboraf®...
-
Nearly 2.1 million new cases of breast cancer are diagnosed worldwide each year, and more than 620,000 people will die from the disease.1 About 15 to 20 percent of women diagnosed with breast cancer...
-
COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of reduced patient mortality The study is the...
-
Konzernverkäufe steigen um 1% zu konstanten Wechselkursen und sinken aufgrund der anhaltenden Wechselkursstärke des Schweizer Frankens in Franken gerechnet um 4% COVID-19-Pandemie wirkt sich im...
-
Un premier semestre marqué par une croissance de 1%1 à taux de change constants et par l’impact significatif de la pandémie de COVID-19 Le chiffre d’affaires consolidé s’inscrit en hausse de 1% à...
-
Group sales increase 1% at constant exchange rates and decline 4% in Swiss francs as a result of continued appreciation of the Swiss franc against most currenciesCOVID-19 pandemic has a negative...
-
In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with monthly ranibizumab eye injections, and a favourable...